Trade Supernus Pharmaceuticals Inc - SUPN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024818% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002596% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 32.03 |
| Open | 31.82 |
| 1-Year Change | 12.04% |
| Day's Range | 31.75 - 32.11 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 19, 2024 | 32.03 | 1.04 | 3.36% | 30.99 | 32.10 | 30.95 |
| Sep 18, 2024 | 31.79 | 0.28 | 0.89% | 31.51 | 32.51 | 31.51 |
| Sep 17, 2024 | 31.67 | 0.27 | 0.86% | 31.40 | 31.87 | 31.40 |
| Sep 16, 2024 | 31.43 | 0.36 | 1.16% | 31.07 | 31.65 | 30.63 |
| Sep 13, 2024 | 31.03 | -0.02 | -0.06% | 31.05 | 31.43 | 30.77 |
| Sep 12, 2024 | 30.83 | -0.22 | -0.71% | 31.05 | 31.51 | 30.42 |
| Sep 11, 2024 | 31.04 | -1.31 | -4.05% | 32.35 | 32.35 | 29.45 |
| Sep 10, 2024 | 33.43 | 0.30 | 0.91% | 33.13 | 34.04 | 33.13 |
| Sep 9, 2024 | 33.86 | 0.77 | 2.33% | 33.09 | 34.20 | 33.09 |
| Sep 6, 2024 | 33.79 | 0.15 | 0.45% | 33.64 | 34.40 | 33.50 |
| Sep 5, 2024 | 34.32 | 0.88 | 2.63% | 33.44 | 35.10 | 33.44 |
| Sep 4, 2024 | 34.93 | 0.70 | 2.04% | 34.23 | 34.95 | 34.20 |
| Sep 3, 2024 | 34.65 | 0.43 | 1.26% | 34.22 | 34.78 | 33.92 |
| Aug 30, 2024 | 35.08 | 0.28 | 0.80% | 34.80 | 35.11 | 34.16 |
| Aug 29, 2024 | 34.91 | 0.29 | 0.84% | 34.62 | 35.02 | 34.53 |
| Aug 28, 2024 | 34.58 | 0.17 | 0.49% | 34.41 | 34.74 | 34.27 |
| Aug 27, 2024 | 34.83 | 0.20 | 0.58% | 34.63 | 34.87 | 34.46 |
| Aug 26, 2024 | 34.83 | -0.11 | -0.31% | 34.94 | 35.34 | 34.64 |
| Aug 23, 2024 | 34.93 | 0.50 | 1.45% | 34.43 | 34.96 | 34.14 |
| Aug 22, 2024 | 34.38 | 0.41 | 1.21% | 33.97 | 34.64 | 33.97 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Supernus Company profile
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes treatments for epilepsy, migraine, hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced parkinson’s disease (PD). Its XADAGO (safinamide) is a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD. Its MYOBLOC (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. Its pipeline of CNS product candidates includes SPN-812, SPN-817, SPN-820, SPN-830 and MYOBLOC.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Supernus Pharmaceuticals Inc revenues increased 12% to $420.7M. Net income decreased 47% to $51M. Revenues reflect Net product sales- Trokendi XR segment increase of 34% to $231.5M, Net product sales-APOKYN segment increase of 70% to $73.3M. Net income was offset by Selling/General/Admin. Expense increase of 47% to $131.4M (expense), Advertising Expense increase of 58% to $59.7M (expense).
Equity composition
Common Stock $0.001 Par, 5/12, 62M auth., 23,912,319 issd. Insiders own approx. 6.73%. IPO:TBA
| Industry: | Proprietary & Advanced Pharmaceuticals |
9715 Key West Avenue
ROCKVILLE
MARYLAND 20850
US
News
RBA Preview: Rates to remain unchanged with inflation-fighting still the focus
RBA Governor Michelle Bullock emphasizes inflation challenges for Australia's economy, citing supply shocks and demand-supply imbalances. Discover insights on CPI trends, interest rates, and the central bank's strategy for managing price pressures in 2024.
12:27, 20 September 2024
BoE Preview: no change expected but forward guidance will be key
The BoE is forecasted to leave rates unchanged in September as UK CPI remains stubborn.
14:53, 19 September 2024
FOMC Decision Review: A 50 point cut but the markets responded in a mixed fashion
Discover the US Federal Reserve’s latest 50 basis point cut and how the markets reacted. Stocks surged, the US Dollar fell, and the Fed hints at more aggressive cuts ahead.
11:30, 19 September 2024
Bank of Japan Preview
The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.
09:40, 17 September 2024
FOMC Decision Preview
As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.
09:48, 16 September 2024
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024
Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com